Calidi Biotherapeutics, Inc.

Calidi Biotherapeutics, Inc. (CLDI) is a clinical-stage biotechnology company developing oncolytic virus-based cancer immunotherapies, with a pipeline concentrated in engineered stem-cell-loaded viral platforms targeting solid tumors. The company pursued public-market access through a merger with First Light Acquisition Group, a blank-check vehicle sponsored by First Light Capital Group that completed its IPO in 2021. The 10-Q filed May 11, 2022, under accession 0001193125-22-146662 represents a quarterly disclosure from the pre-combination period, when the SPAC was still completing its search and deal process in the biotechnology and oncology sector. The de-SPAC transaction closed in 2023, with the combined company trading on NYSE American under the CLDI ticker. Sign up at SpacDesk for full filing history, deal analytics, and real-time SPAC research on CLDI and every active transaction in the market.